Aethlon Medical Announces the Grant of a U.S. Patent Protecting Methods of Capturing MHC Antigen Associated Exosomes

SAN DIEGO, July 19, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the United States Patent and Trademark Office has granted U.S. Patent Number 9,707,333 (the '333 Patent), entitled "EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES."

The '333 Patent covers methods of capturing exosomes that include an MHC-I or MHC-II antigen, whereby a patient suspected of receiving a benefit from exosome capture and removal is selected, and the whole blood, plasma, or serum from the patient is contacted with a substrate that includes antibodies specific for an MHC-I or MHC-II antigen.  The '333 Patent also covers methods of capturing and removing MHC-I or MHC-II antigen associated exosomes from whole blood, plasma, or serum of a patient, and returning the whole blood, plasma, or serum to the patient with substantially fewer MHC-I or MHC-II antigen associated exosomes.

MHC-I and MHC-II antigen associated exosomes contribute to the progression of numerous disease conditions, including cancer, autoimmune disorders and neurodegenerative diseases.

The '333 Patent is a continuation of U.S. Patent Number 9,364,601, which covers methods of lectin-based capture of exosomes from a patient, and U.S. Patent Number 8,288,172, which protects the use of the Aethlon Hemopurifier® in a method to remove immunosuppressive exosomes from blood. Together, these patents solidify Aethlon's position as a leader in pioneering diagnostic and therapeutic strategies in the field of exosome biology.

Aethlon Chairman and CEO Jim Joyce stated, "In addition to expanding our intellectual property portfolio, the issuance of the '333 patent further reinforces our competitive position within the emerging industry for therapeutic strategies to inhibit the proliferation of disease-promoting exosomes."

About Aethlon Medical, Inc.

Aethlon Medical creates medical technologies to address unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. The Company believes the Hemopurifier® can achieve the broad-spectrum countermeasure goal set forth by the U.S. Department of Health and Human Services (HHS). The device has been validated to capture Ebola, Zika, Lassa, MERS-CoV, HIV, Hepatitis C, Cytomegalovirus, Epstein-Barr, Herpes Simplex, Chikungunya, Dengue, West Nile, Smallpox related viruses, H1N1 Swine Flu, H5N1 Bird Flu, and the reconstructed Spanish flu virus of 1918. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, including products related to the recently issued  '333 Patent, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2016 and on Form 10-K to be filed for the year ended March31, 2017, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
[email protected]

Investor Relations:
John Marco
CORE IR
516 222 2560
[email protected]

SOURCE Aethlon Medical, Inc.